Platelet aggregation inhib 
Welcome,         Profile    Billing    Logout  
 37 Companies  30 Products   30 Products   118 Diseases   375 Trials   19183 News 


«12...891011121314151617181920»
  • ||||||||||  Journal:  Prostaglandin E1 Is an Efficient Molecular Tool for Forest Leech Blood Sucking. (Pubmed Central) -  Jan 26, 2021   
    To the best of our knowledge, this is the first report on PGE1 in invertebrates. The functions of PGE1, such as vasodilation, platelet aggregation inhibition, anti-inflammation, and pain alleviation, may facilitate the ingestion of host blood by leeches.
  • ||||||||||  selatogrel (ACT-246475) / Idorsia
    Clinical, Journal:  Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. (Pubmed Central) -  Jan 13, 2021   
    P2
    Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-related antiplatelet response. (A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack; NCT03487445, 2018-000765-36 [EudraCT]).
  • ||||||||||  aspirin / Generic mfg., clopidogrel / Generic mfg., prasugrel / Generic mfg.
    Clinical, Journal:  Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. (Pubmed Central) -  Jan 13, 2021   
    P4
    The primary goal of this trial is to study the benefits of treating only those patients that cannot activate clopidogrel with an alternative that has shown to be a more effective platelet inhibitor and does not require bioactivation by the cytochrome P450 enzyme. We expect an improvement in net clinical benefit outcome in the active arm patients, thus supporting pharmacogenetic testing in PCI patients post STEMI.
  • ||||||||||  clopidogrel / Generic mfg.
    Retrospective data, Journal:  Predictors of Clopidogrel Hyper-Responsiveness in Neuro-Interventional Procedures. (Pubmed Central) -  Jan 5, 2021   
    These results are useful to predict perioperative hemorrhagic complications. Considering dose reduction of clopidogrel or alternative drugs in high risk cases is necessary to prevent perioperative hemorrhagic complications.
  • ||||||||||  setanaxib (GKT831) / Genkyotex
    Journal:  VAS2870 and VAS3947 attenuate platelet activation and thrombus formation via a NOX-independent pathway downstream of PKC. (Pubmed Central) -  Jan 2, 2021   
    Unlike VAS compounds, concurrent inhibition of NOX1, 2, and 4 by treatment with ML171, GSK2795039, and GKT136901/GKT137831 did not affect thrombin and U46619-induced platelet aggregation...This study is the first to demonstrate that, in addition to inhibiting NOX activity, VAS compounds reduced platelet activation and thrombus formation through a NOX-independent pathway downstream of PKC. These findings also indicate that VAS compounds may be safe and potentially therapeutic agents for treating patients with cardiovascular diseases.
  • ||||||||||  clopidogrel / Generic mfg., prasugrel / Generic mfg.
    Retrospective data, Journal, Adverse events:  Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases. (Pubmed Central) -  Dec 30, 2020   
    After adjustment for known confounders including age, sex, and concomitant medications (aspirin, anticoagulants, and proton pump inhibitors), the hemorrhagic risk of prasugrel compared with clopidogrel remained significant (adjusted reporting odds ratios [95% CI] for total, intracranial, and gastrointestinal hemorrhagic events = 2.42 [1.97-2.96], 2.45 [1.85-3.24], and 2.27 [1.73-2.97] in JADER, and 2.21 [2.09-2.34], 1.21 [1.09-1.33], and 1.41 [1.29-1.54] in FAERS). The hemorrhagic risk was found to be greater with prasugrel than clopidogrel in real-world patients, including Japanese patients.
  • ||||||||||  Journal:  The G-protein βγ subunits regulate platelet function. (Pubmed Central) -  Dec 16, 2020   
    Our findings demonstrate, for the first time, that Gβγ subunits directly regulate GPCR-dependent platelet function, in vitro and in vivo. Moreover, these data highlight Gβγ as a novel therapeutic target for managing thrombotic disorders.
  • ||||||||||  deferiprone / Generic mfg.
    Journal:  Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition. (Pubmed Central) -  Nov 27, 2020   
    Moreover, the results from molecular docking showed that deferiprone interacted closely with key residues in the peroxidase active site of COX-1. These results suggested that deferiprone possessed antiplatelet activity mainly through the inhibition of COX-1 activity.
  • ||||||||||  epinephrine / Generic mfg.
    Journal:  Role of Kv1.3 Channels in Platelet Functions and Thrombus Formation. (Pubmed Central) -  Nov 26, 2020   
    We showed specific inhibition of Kv1.3 by the novel monoclonal antibody 6E12#15 suppressed platelet functions and platelet-dependent thrombosis through modulating platelet [Ca] elevation. These results indicate that Kv1.3 could act as a promising therapeutic target for antiplatelet therapies.
  • ||||||||||  Journal:  Antiplatelet Effect of Carbon Monoxide Is Mediated by NAD and ATP Depletion. (Pubmed Central) -  Nov 26, 2020   
    These results indicate that Kv1.3 could act as a promising therapeutic target for antiplatelet therapies. The antiplatelet effect of CO is mediated by inhibition of mitochondrial respiration-attributed to the inhibition of cytochrome c oxidase, and inhibition of glycolysis-ascribed to cytosolic NAD+ depletion.
  • ||||||||||  Journal:  Resveratrol inhibits Ca signals and aggregation of platelets. (Pubmed Central) -  Nov 26, 2020   
    The antiplatelet effect of CO is mediated by inhibition of mitochondrial respiration-attributed to the inhibition of cytochrome c oxidase, and inhibition of glycolysis-ascribed to cytosolic NAD+ depletion. The results suggest that resveratrol inhibits thrombin-induced platelet aggregation through decreasing Ca release from its stores and inhibiting store-operated Ca influx into platelets.
  • ||||||||||  Review, Journal:  Mechanisms of the protective effects of nitrate and nitrite in cardiovascular and metabolic diseases. (Pubmed Central) -  Nov 25, 2020   
    In this review, we focus on nitrate/nitrite bioactivation, as well as the potential mechanisms for nitrate/nitrite-mediated effects on cardiovascular and metabolic diseases. Understanding how dietary nitrate and nitrite induce beneficial effect on cardiovascular and metabolic diseases could open up novel therapeutic opportunities in clinical practice.
  • ||||||||||  aspirin / Generic mfg.
    Clinical, Journal:  Role of aspirin and statin therapy in patients with cerebral cavernous malformations. (Pubmed Central) -  Nov 12, 2020   
    A GLMM showed that patients in the combined therapy group to have significantly lower odds of having an acute hemorrhage at diagnosis compared to the reference group of no therapy (OR 0.24; 95% CI 0.09-0.59; P = 0.002). Patients with a CCM receiving therapy with both aspirin and statins were less likely to present at diagnosis with acute hemorrhage.
  • ||||||||||  aspirin / Generic mfg., clopidogrel / Generic mfg.
    Preclinical, Journal:  Monitoring antiplatelet aggregation in vivo and in vitro by microtiter plate method. (Pubmed Central) -  Nov 3, 2020   
    The improved microtiter plate method combining the use of multiple levels of multiple agonists avoids the variation of the effective inducer concentrations due to individual different response of platelets to agonists. It may be a potential approach in the detection of platelet aggregation.
  • ||||||||||  aspirin / Generic mfg.
    Journal:  Personalization of Aspirin Therapy Ex Vivo in Patients with Atherosclerosis Using Light Transmission Aggregometry. (Pubmed Central) -  Nov 1, 2020   
    Personalizing ASA therapy in 81 mg ASA non-sensitive patients with escalating dosages of ASA demonstrated that 6 patients became sensitive to a dosage equivalent to 162 mg ASA and 3 patients became sensitive to a dosage equivalent to 325 mg ASA. We were able to personalize ASA dosage ex vivo in all ASA non-sensitive patients with escalating dosages of ASA within 1 h of testing.
  • ||||||||||  carvedilol / Generic mfg.
    Journal:  Effect of carvedilol on arteriovenous graft primary patency. (Pubmed Central) -  Oct 30, 2020   
    We were able to personalize ASA dosage ex vivo in all ASA non-sensitive patients with escalating dosages of ASA within 1 h of testing. The results of this study indicate that the use of carvedilol for more than 84 days improves the primary patency of AVGs, but the use of carvedilol for less than 84 days does not.
  • ||||||||||  Miostat (carbachol) / Novartis
    Journal:  Pharmacological Modulation of Smooth Muscles and Platelet Aggregation by Psidium cattleyanum. (Pubmed Central) -  Oct 28, 2020   
    For the evaluation of tracheorelaxant activity, isolated tracheal tissue was treated with High-K (80 mM) and carbachol (CCh) and then challenged cumulatively with Pc.Cr...Dose-dependent hypotension was seen in normotensive rats when treated with Pc.Cr intravenously. This study showed the spasmolytic, tracheorelaxant, vasodilator, platelet aggregation inhibitory, antidiarrheal, and hypotensive activities of P. cattleyanum which may be due to the blockage of calcium channels, but the involvement of any other pathway cannot be ignored.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Antithrombotic therapy for postinterventional management of peripheral arterial disease. (Pubmed Central) -  Oct 27, 2020   
    The decision to initiate intensified antithrombotic therapy should include a close examination of its risk-benefit profile. The demonstrated benefit of such treatment is restricted to the prevention of index artery reocclusion, while an increased risk of bleeding may lead to significant morbidity and mortality.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, Bayer
    Clinical, Journal:  Current concepts of anticoagulant and antiplatelet therapy in patients with vascular pathology (Pubmed Central) -  Oct 20, 2020   
    Therefore, availability of modern antithrombotic drugs favourably contributing to a more personified approach to treatment is of utmost importance. Thus, for example, rivaroxaban, an anticoagulant belonging to the class of direct-acting oral factor Xa inhibitors, provides a possibility to select an optimal dosage and regimen for a particular patient with arterial or vascular pathology in practice of a cardiovascular surgeon.
  • ||||||||||  [VIRTUAL] WARM AUTOIMMUNE HEMOLYTIC ANEMIA AS A RARE CAUSE OF PULMONARY EMBOLISM () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_2423;    
    There is a paucity of controlled trials in this setting that needs to be addressed. Clinicians should consider antithrombotic prophylaxis when concomitant risk factors such as hospitalization, severe onset of disease or splenectomy are present.